Integrated DNA Technologies (IDT), a prominent player in genomics, has partnered with Profluent Bio, an innovator in AI-driven protein design, to enhance the development of next-generation enzymes. This collaboration merges Profluent’s advanced generative AI platform with IDT’s extensive knowledge in enzymology and genomics, opening new avenues for creating novel enzyme variants. It also reinforces IDT’s innovation hub in the Bay Area, underscoring its dedication to advancing synthesis technologies and supporting growth in oncology research.

“At IDT, we’ve built a strong enzyme engineering capability—innovating proprietary enzymes that have powered countless scientific breakthroughs,” stated IDT President Ajay Gannerkote. He further emphasized that “this collaboration with Profluent Bio represents a bold step forward in our strategic roadmap. By integrating Profluent’s AI-driven protein design with IDT’s enzymology and genomics expertise, we will unearth new possibilities across a broad range of critical applications, from epigenetics to cancer research and beyond.”

Profluent's CEO, Ali Madani, PhD, remarked, “Pairing Profluent’s AI with IDT’s world-class enzymology and manufacturing expertise is a powerful way to bring new capabilities to researchers and the industry. This partnership reflects our belief that AI-designed proteins can unlock step-changes in enzyme efficiency, precision, and manufacturability, without being constrained by what evolution has already tried.”

The foundation of Profluent’s models, including the latest ProGen3, is built on the Profluent Protein Atlas, which comprises a curated multibillion-sequence dataset for comprehensive biological insights and precise experimental alignment. These models have already made significant contributions, exemplified by innovations like OpenCRISPR-1™, the first AI-generated gene editor.

IDT is set to utilize its enzyme development infrastructure, genomics expertise, and global manufacturing capabilities to test, validate, and scale the sequences designed by Profluent, thus fueling its new product innovation pipeline. As part of Danaher, which is investing in AI for molecular design, IDT is strategically positioned to expedite the transition of AI-driven designs into high-performance, production-ready enzymes. This partnership not only reflects IDT's commitment to advancing enzyme innovation but also propels its innovation engine and enhances the customization of its novel enzymology capabilities for next-generation sequencing, synthetic biology, and gene editing.

By combining Profluent’s AI-driven design with IDT’s specialized knowledge, the collaboration is designed to streamline the transition from in silico designs to effective biological tools, enhancing speed, scalability, and scientific impact.